학술논문
Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma
Document Type
article
Author
Jeffrey J. Wallin; Johanna C. Bendell; Roel Funke; Mario Sznol; Konstanty Korski; Suzanne Jones; Genevive Hernandez; James Mier; Xian He; F. Stephen Hodi; Mitchell Denker; Vincent Leveque; Marta Cañamero; Galina Babitski; Hartmut Koeppen; James Ziai; Neeraj Sharma; Fabien Gaire; Daniel S. Chen; Daniel Waterkamp; Priti S. Hegde; David F. McDermott
Source
Nature Communications, Vol 7, Iss 1, Pp 1-8 (2016)
Subject
Language
English
ISSN
2041-1723
Abstract
Cancer immunotherapy can be used in combination with other therapies for a better response. Here, the authors conduct a phase Ib clinical study and report the clinical activity and the immune response of the anti-PDL1 agent, atezolizumab, in combination with bevacizumab in ten patients with metastatic renal cell carcinoma.